Sponsored
News

Revna Biosciences Advances Cancer Research Adding To Previous FDA Approvals

Sponsored
Sponsored

Revna Biosciences (RevnaBio), a leading precision medicine company based in Ghana, is making strides in its mission to address unmet needs in cancer care. The company announced that data from its ongoing Ghana FDA-mandated cancer clinical research covering solid and blood cancers has begun supporting product registration. This achievement comes a few months after RevnaBio successfully introduced advanced molecular tests in infectious diseases and maternal and child health.

RevnaBio’s latest feat marks a significant step towards addressing West Africa’s lack of advanced molecular diagnostic testing for cancer. The company’s commitment to enhancing regional biomedical capabilities is evident in its technology localisation efforts. In collaboration with precision medicine leader Diatech Pharmacogenetics, RevnaBio is addressing patients’ needs today for improved diagnostics and treatment options in future. The company’s approach uses Diatech’s EasyPGX & the Myriapod platforms, which provide qPCR IVD and NGS tests, the most comprehensive solutions for cancer precision medicine – a first in West Africa.

The Chief Executive Officer of Diatech Pharmacogenetics, Oliva Alberti, said,

“We are proud to collaborate with Revna Biosciences in this groundbreaking endeavour. Together, we’re making personalised therapy more accessible in West Africa. Our role is to develop comprehensive assays for molecular profiling to aid in the fight against cancer. We’re doing our part towards a future where every patient can access advanced molecular diagnostic testing.”

Dr Derrick Akpalu, Co-Founder and CEO of Revna Biosciences, expressed optimism about the impact of their new developments; he said,

“We are pioneering today for a healthier tomorrow. At full deployment, the EasyPGX platform offers up to 80% liquid biopsy capability, ensuring patients can have a blood draw for cancer testing here in West Africa. We are positive this will enhance our ongoing oncology research and clinical care efforts.”

Dr Akpalu also acknowledged the invaluable contributions of research participants and collaborating investigators from various teaching hospitals across Ghana. He added,

“Many thanks to our collaborating investigators at the Korle Bu Teaching Hospital, the 37 Military Teaching Hospital, the Cape Coast Teaching Hospital and the Sweden Ghana Medical Center for partnering with us. We look forward to activating many more study sites and sharing insights from this pivotal study as the study further matures.”

Sponsored
Alinnor Arinze

Recent Posts

2027: Yayi Unveils Manifesto, Promises 50,000 Jobs Annually In Ogun State

The APC governorship candidate in Ogun State, Senator Solomon Olamilekan Adeola (Yayi), has unveiled his…

6 hours ago

Ogun 2027: Egbaland Backs Yewa Power Shift, Declares Collective Support For Yayi — Says Ishola

Egbaland has declared its collective support for the emergence of Yewa as the next political…

6 hours ago

Nigerian U17 International Raheem Salaudeen Continues Football & Academic Development At Brooke House College, England

From Buruj Football Club and Buruj Sports Academy in Nigeria to Brooke House College in…

7 hours ago

Giwa Gardens 3.0: How AI, Recreational Real Estate and Infrastructure Can Help Unlock Nigeria’s $100 Billion Tourism Opportunity

BY KEJI GIWA As Nigeria pursues its ambitious target of generating $100 billion in GDP…

11 hours ago

United Nigeria Airlines Launches Jos Flights To Lagos, Kano, Owerri From November 24, 29

United Nigeria Airlines will begin scheduled flight operations linking Jos, the Plateau State capital, with…

13 hours ago

When Opposition Loses The Plot: Dele Momodu, Politics Of Animosity And The Burden Of Responsible Criticism

OMOGBOLAHAN L.A. BABAWALE There is a world of difference between being an opposition figure and…

13 hours ago
Sponsored